Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • EO2463 Peptide Immunotherapy Shows Promise in Follicular and Marginal Zone Lymphoma丨18-ICML

    19- EO2463 Peptide Immunotherapy: Innovation Based on the Oncomimics Concept EO2463 is a “ready-to-use” peptide immunotherapy based on the “Oncomimics” concept, whose uniqueness lies in leveraging the host’s pre-existing immune…

    2025.09.04
  • New Era in Non-Hodgkin Lymphoma: Professor Franck Morschhauser on Breakthrough Phase I Results of a Novel BCL6 Degrader

    Unmet Clinical Need: The Dilemma of Relapsed/Refractory Non-Hodgkin Lymphoma Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) remain challenging problems in the field of hematological oncology, especially for…

    2025.09.04
  • Extranodal Lymphoma Treatment Enters a New Era: IELSG’s 30-Year Journey of Academic Breakthroughs and Future Prospects丨Memorial Lecture

    Legacy and Tribute Professor Emanuele Zucca. Since his graduation from the University of Milan in 1983, Professor Zucca has been dedicated to clinical research. With his profound expertise in clinical…

    2025.09.03
  • A New Era in Molecular Subtyping of Aggressive B-cell Lymphoma: Professor David W. Scott on Genomics-Guided Precision Therapy丨EHA 2025

    Current Status and Challenges in the Classification of Aggressive B-cell Lymphoma “The classification systems we currently use, whether the International Consensus Classification (ICC) or the 5th edition of the World…

    2025.09.03
  • The Journey of Disease Discovery: Professor Elaine Jaffe Reviews a Century of Lymphoma Diagnosis and Classification

    The Microscope: An Enduring Tool for Disease Discovery and Rudolf Virchow’s Legacy In today’s rapidly advancing modern medicine, despite the rapid development of molecular biology techniques, the microscope, as a…

    2025.09.03
  • Professor Bruce D. Cheson on Breakthroughs in Lymphoma Treatment: Innovation Pathways and Future Vision丨EHA 2025

    Dreams, Luck, and a Little Bit of Crazy – The Transformative Journey of Lymphoma Treatment Professor Cheson began his speech by emphasizing that to foresee the future, one must first…

    2025.09.03
  • Professor Yuzhu Shi: The Comprehensive Value of Abdominal CT in Managing Post-Transplant Complications丨13th Lu Daopei Hematology Conference

    PART 1 Abdominal complications are a major challenge in post-HSCT management. Compared with other imaging modalities or laboratory tests, what do you consider the unique advantages and core clinical value…

    2025.09.03
  • Professor Hui Wang: Advancing MRD Detection in AML—From Standardization and Automation Toward Personalized Treatment

    PART 1 MRD monitoring plays a vital role in prognosis and guiding individualized treatment strategies in AML. What do you consider the most significant advances in flow cytometry for MRD…

    2025.09.03
«previous next»
Recent Posts
  • CSCO 2026 | Professor Yungan Tao: Perioperative Immunotherapy Combined with Local Treatment Is Reshaping the Head and Neck Cancer Treatment Landscape 
  • Growing Alongside CSCO | Professor Rui Ge: Gaining Knowledge and Friendship at CSCO While Exploring the Path to Precision Oncology 
  • CSCO: A Global Perspective | Leaders from ASCO, ESMO, and CSCO Convene to Discuss a New Landscape for Global Collaboration in Cancer Care 
  • Professor Wing Cheong Chow: Controversies, Risk-Stratified Pathways, and Localization of Breast Cancer Screening Strategies in Asia | 2026 Lingnan Breast Cancer Academic Forum
  • CSCO 2026 | Professor Qiang Wei: Real-World Evidence Further Validates the Clinical Benefits of Enzalutamide-Based Combination Therapy in Older, Frail, and Comorbidity-Burdened Patients With mCSPC
Recent Comments
    Archives
    • October 2026
    • September 2026
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top